Maggie O’Neill is a health writer and reporter based in New York who specializes in covering medical research and emerging wellness trends, with a focus on cancer and addiction. Prior to her ...

The Food and Drug Administration (FDA) recently removed Eli Lily's weight-loss drug from its shortage list, which some industry officials and medical experts argue will complicate access for some ...

On October 7, a compounding trade group filed a lawsuit challenging the agency's action, saying there was still a shortage of the wildly popular drug. HealthDay News — Pharmacists may continue ...

In a reversal, the Food and Drug Administration (FDA) said it will allow some compounding pharmacies to temporarily make their own versions of tirzepatide, the active ingredient in Eli Lilly’s ...

On October 3, 2024, the US Food and Drug Administration (FDA) revised its shortage categorization of tirzepatide, a glucagon-like peptide 1 (GLP-1) medication, marking the shortage as “resolved ...

Pharmacists can continue making compounded versions of generic tirzepatide, the active ingredient in popular medications Mounjaro and Zepbound, the Food and Drug Administration said in a recent ...

Nearly 250,000 people in England could access a weight loss injection on the NHS. Tirzepatide is prescribed for type 2 diabetes, but has been shown in clinical trials to be effective for weight loss.

Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the U.S. Food and Drug Administration revisits its Oct. 2 decision to remove the medicine from a ...